Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment

In a randomized clinical trial in patients initiating glucocorticoid therapy (GC‐I) or on long‐term therapy (GC‐C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Geusens, Piet, Bevers, Melissa SAM, van Rietbergen, Bert, Messina, Osvaldo D, Lespessailles, Eric, Oliveri, Beatriz, Chapurlat, Roland, Engelke, Klaus, Chines, Arkadi, Huang, Shuang, Saag, Kenneth G, van den Bergh, Joop P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324223/
https://www.ncbi.nlm.nih.gov/pubmed/35340062
http://dx.doi.org/10.1002/jbmr.4551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324223/
https://www.ncbi.nlm.nih.gov/pubmed/35340062
http://dx.doi.org/10.1002/jbmr.4551

Ejemplares similares